ClinicalTrials.gg
RecruitingNCT06007872Updated Nov 9, 2026

Intracardiac Echocardiography Guided Watchman Device Implant

An interventional study of Intracardiac Echocardiography (ICE) in Atrial Fibrillation and Left Atrial Appendage Thrombosis, sponsored by The Cleveland Clinic. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by The Cleveland Clinic · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Registered 8 months after the study started (first participant enrolled Dec 2022, registered Aug 2023).
  • Started Dec 2022; still recruiting 3 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 26 studies in Atrial Fibrillation by The Cleveland Clinic — 10 open to participants now, 11 under way, 1 of them phase 3. Atrial Fibrillation · The Cleveland Clinic.

Planned enrollment
4th of 13
100 · median 90
Started
2022
with 1 other
No phase
9 of 26
3 open now
Primary completion
2027-12
later than 4 of 10 live
Registered
18th of 26
by date

Among the 26 studies in Atrial Fibrillation by The Cleveland Clinic, this one is the 4th largest by planned enrollment of the 13 interventional ones that give a count, is one of 2 that started in 2022, is one of 9 with no phase, reaches primary completion later than 4 of the 10 other live ones, and was the 18th registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

10 of the 26 studies in Atrial Fibrillation by The Cleveland Clinic are open now, in 1 country. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 10 open studies →

Where they have run

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Atrial Fibrillation by The Cleveland Clinic, or all of them as a file.
02

Study summary

This study is to look at the success of Intracardiac Echocardiography (ICE) in the Watchman procedure. Currently the process is to use a Transesophageal Echocardiography (TEE) to place the Watchman in patients. This study is aiming to show how the ICE is just as effective in placing the device correctly and effectively.

Read the detailed description

Left atrial appendage occlusion is approved as an indicated therapy for patients with non valvular atrial fibrillation, high risk of stroke and an appropriate rationale for avoidance of long term use of oral anticoagulants.

Concurrent procedural TEE is an integral part of the procedure. It is used to guide trans-septal puncture, device sizing and assessment of final adequacy of device implant.

TEE requires the participation and guidance of a cardiac imager and because the TEE probe is in place for a relatively long duration the procedure, the procedure is most commonly performed under general anesthesia. Furthermore TEE can be associated with risk of injury to the oropharynx and esophagus. Our ongoing clinical experience and known literature suggest that TEE may not be necessary for the overall success of the procedure. The objective of the study is to investigate a new work flow that may ultimately demonstrate that intra-procedural TEE may not be necessary, obviating the need for additional personnel, general anesthesia and decreasing overall risk. ICE has been widely used to aid trans-septal puncture and visualize left atrial anatomy. Smaller studies and case series have reported the use of ICE as an alternative to TEE in guiding Watchman device implant. This has not been compared systematically with TEE in a large patient sample.

03

Conditions studied

  • Atrial Fibrillation
  • Left Atrial Appendage Thrombosis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All patients who meet guideline established criteria for commercially available Watchman device implant and not enrolled in an active clinical trial

Exclusion criteria

Exclusion Criteria:

  • Patients in whom a procedural TEE cannot be performed and an ICE only implant is needed.
  • Patients receiving a concomitant ablation procedure
  • Patients with prior incomplete surgical or percutaneous left atrial appendage ligation/exclusion procedures
  • Patients in whom the delivery of trans-septal equipment is anticipated to be difficult (e.g. patent foramen ovale (PFO) or atrial septal defect (ASD) closure devices in place).
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Intervention

    Intracardiac Echocardiography (ICE)

    Device: Intracardiac Echocardiography (ICE)

Interventions

  • DeviceIntracardiac Echocardiography (ICE)

    ICE will be used to guide trans-septal puncture and to guide device implant.

06

What researchers measure

Primary outcomes

  1. Successful Watchman implantation using intracardiac echocardiography (ICE) guidance

    Intracardiac echocardiography (ICE) guided Watchman placement confirmed by transesophageal echocardiography (TEE)

    Time frame: During the procedure

07

Study locations

1 of 1 sites recruiting
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
    Recruiting
    • Oussama Wazni, MD · Contactwaznio@ccf.org · 216-444-2131
    • Oussama Wazni, MD, MBA · Principal investigator
    • Walid Saliba, MD · Sub investigator
    • Mohamed Kanj, MD · Sub investigator
    • Tyler Taigen, MD · Sub investigator
    • Serge Harb, MD · Sub investigator
    • Rhonda Miyasaka, MD · Sub investigator
    • Samir Kapadia, MD · Sub investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2022 (actual). Primary completion is estimated for Dec 2027, 60 months after the start.

Of 797 non-industry interventional studies with no phase under Atrial Fibrillation, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's planned 60 months is above that.

Counting every sponsor, half of 1,052 studies reached it within 33 months; a quarter within 18 and three quarters within 54.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 17, 2023
First posted
Aug 23, 2023
StartActual
Dec 2, 2022
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2027
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Nov 9, 2026
Show all 1 update
  1. Nov 9, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06007872
Responsible party
Oussama Wazni (Principal Investigator, The Cleveland Clinic) — Principal investigator
First posted
Aug 23, 2023
Start date
Dec 2, 2022
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Nov 9, 2026

Study contacts

Oussama Wazni, MD
Contact
waznio@ccf.org
216-444-2131
Oussama Wazni, MD
principal investigator · The Cleveland Clinic

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion